BD (NYSE: BDX) announced the commercial launch of its CentroVena One Insertion System, described as the first all-in-one central venous catheter insertion device on the market. The system consolidates essential components including the introducer needle, syringe, guidewire and catheter into a single platform.

According to the company, the system reduces procedural steps by 30% and insertion time by 50% compared to traditional methods, based on a simulation study published in The Journal of Emergency Medicine in December 2025. The device received U.S. FDA 510(k) clearance and was accepted into the FDA Safer Technologies Program for Medical Devices.

UNC Health Blue Ridge is among the first health systems to pilot the system in patient care as part of an initial clinical evaluation. "What stands out in our early experience with CentroVena One is its intentional design around real-world clinical challenges," said Anthony Frank, chief medical officer at UNC Health Blue Ridge.

The system features a pre-loaded kink-resistant guidewire, integrated drape clip designed to prevent guidewire embolism, pre-loaded catheter with self-dilating tip, and introducer needle with integrated passive needle safety. The closed insertion system aims to reduce risks of air embolism and blood exposure.

Central line insertion is performed millions of times annually in the U.S., but traditional processes involve multiple component exchanges that can introduce contamination and increase complication risks including pneumothorax, arterial injury, and bloodstream infections.

The commercial launch marks BD's entry into the acute central venous catheter market and expands its vascular access portfolio. The product is now commercially available in the U.S., according to the company's press release statement.